YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news…
(RTTNews) - Even with strong research and disciplined stock selection, an investor may not get every stock pick right. As legendary investor Peter Lynch once said, "In this business, if you're good, you're right six times out of ten. You'r…
(RTTNews) - Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tecto…
TORONTO, June 17, 2026 /CNW/ - TD Asset Management Inc. ("TDAM") today announced the June cash distributions for the TD Exchange-Traded Funds (each, a "TD ETF" and collectively, the "TD ETFs") and TD Mutual Fund ETF Series (each, a "TD ETF…
(RTTNews) - Tectonic Therapeutics Inc. (TECX), a clinical-stage biotechnology company, on Wednesday announced completion of enrollment in the Phase 2 APEX trial for TX45 in treating pulmonary hypertension associated with heart failure with…
TORONTO, March 19, 2026 /CNW/ - TD Asset Management Inc. ("TDAM") today announced the March cash distributions for the TD Exchange-Traded Funds (each, a "TD ETF" and collectively, the "TD ETFs") and TD Mutual Fund ETF Series (each, a "TD E…
(RTTNews) - Tectonic Therapeutics, Inc. (TECX), a clinical-stage biotechnology company, reported fourth-quarter and full-year 2025 results and provided an update on the progress of its clinical pipeline, including recent achievements and u…
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed TX4…
Tectonic Therapeutic WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and an…
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulat…
TORONTO, Dec. 22, 2025 /CNW/ - TD Asset Management Inc. ("TDAM") today announced the December cash distributions for the TD Exchange-Traded Funds (each, a "TD ETF" and collectively, the "TD ETFs") listed below. Unitholders of record as of…
TORONTO, Dec. 22, 2025 /CNW/ - TD Asset Management Inc. ("TDAM") today announced the final annual 2025 reinvested distributions for certain TD Exchange-Traded Funds listed below (collectively, the "TD ETFs"). These annual reinvested distri…
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating Stocks chart On November 18, LifeSci Capital reiterated a Bu…
[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap sto…
TORONTO, Nov. 20, 2025 /CNW/ - TD Asset Management Inc. ("TDAM") today announced the estimated 2025 reinvested distributions for TD Exchange-Traded Funds (each, a "TD ETF" and collectively, the "TD ETFs") listed below. These annual reinves…
(RTTNews) - Tectonic Therapeutic, Inc. (TECX) jumped 12.33% to $20.92, gaining $2.30, after announcing positive topline results from its Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension associated with…
[Percentage Symbol with Slash Transforming into Upward Growth Graph Representing Financial Gains and Market Trends] J Studios * Tectonic Therapeutic (TECT) has skyrocketed ~29% in after-hours trading Wednesday after posting positive phase…
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolerated in patients with PH‑HFrEF with no serious…
[Sign for Wall Street in New York City] Pharrel Wiliams * Oppenheimer has initiated coverage of Tectonic Therapeutic (NASDAQ:TECX [https://seekingalpha.com/symbol/TECX]) with an outperform rating citing the company's heart failure candidat…
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT CARM [https…
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT CARM [https://www.chartmill.com/stock/qu…
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT CARM [https://www.c…
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT CARM [https://ww…
WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulat…
Key Points Research and development spending increased 142.3% year over year to $17.2 million in Q2 2025, compared to $7.1 million in Q2 2024, driven by clinical trial activity. Cash and cash equivalents stood at $287.4 million as of Q2 20…
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulat…
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On June 10, Raymond James resumed coverage of Tectonic Therapeutic, Inc. (NASDAQ:TECX) with an Outperform rating and set a $76 price target…
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”)In new echoca…
Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection…
Building a strong portfolio naturally hinges on choosing the right stocks. The tricky part? Finding them. With thousands of publicly traded companies and a flood of investment ‘methods’ floating around, it’s no wonder even seasoned investo…
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-H…
WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “…
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpoints and patient population in ongoing…